3e Bioenergy International LLC
3E BIOENERGY INTERNATIONAL LLC aims to apply state-of-the-art knowledge in genetics, genomics and biotechnology for the enhancement of sweet sorghum's potential as a feedstock for the bioenergy industry.
Ascendia Pharmaceuticals LLC
Ascendia is a speciality pharmaceutical company dedicated to developing enhanced formulations of existing drug products, and enabling formulations for pre-clinical and clinical stage drug candidates. Ascendia specializes in creating formulations for poorly-water soluble molecules using nano-particle technologies. Ascendia assesses the feasibility of a broad array of formulation options in order to improve a drug’s bioavailability. Ascendia’s technologies include nano-emulsions, amorphous solid dispersions, and production of nano-crystals. Ascendia provides development and testing services - from discovery-stage molecules to life-cycle-management projects - creating formulation solutions with enhanced biopharmaceutical properties suitable for clinical scale-up.
For more information visit us at www.ascendiapharma.com or contact:
Troy Harmon, VP, Business Development, firstname.lastname@example.org
Aucta Pharmaceuticals, LLC
Aucta Pharmaceuticals, LLC. (AUCTA, latin-improved, enhanced) is founded by experienced pharmaceutical research scientists from the U.S. and China, and managed by U.S. pharma industry veterans. The company is located in both China and New Jersey. Their expertise is new drug product development, product label improvement and solving difficult technical issues. They have solid fundamentals and sophisticated technology platform that can rapidly tackle technical issues and propose new product concept. The company will be in the business of novel and generic formulation product development. They work with pharma companies around the world for product co-development, sponsored research and provide value adding solutions to their partners and projects.
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac diseases. The mission is to develop well-studied molecules deployed through innovative delivery systems to treat diseases with significant unmet clinical need. They are currently developing three product candidates, two based on their proprietary pulsatile nitric oxide delivery device, which is referred to as INOpulse, and a third device which is referred to as bioabsorbable cardiac matrix, or BCM.
BioAegis Therapeutics Inc.
BioAegis Therapeutics Inc. is a clinical stage entity commercializing groundbreaking discoveries in inflammation and infection, directed at addressing serious diseases. The Company is pursuing a portfolio of high value indications based on repletion of plasma gelsolin, an integral and ubiquitous, natural human protein.
Crystal Pharmatech is a technology-driven contract research organization (CRO) that focuses on materials science and engineering for drug development. They partner with clients to ensure comprehensive solutions for their needs in solid-state research, crystallization process development, and preformulation studies. They guide clients in the discovery and selection of the optimal solid phase for drug development using all aspects of pre-formulation studies, including API process and formulation development, regulatory support and intellectual property protection.
FluiDda Inc. is a spinoff company from the University of Antwerp whose main focus is developing imaging biomarkers to enhance drug development and patient care. These biomarkers combine biomedical imaging and advanced engineering methods resulting in a proprietary CT/CFD Pulmonary Imaging Technology that can be used as a diagnostic and research tool. The company technology has been validated in twenty clinical trials and has been focused on respiratory diseases such as asthma, COPD, and sleep apnea.
GeneAssess is a biotechnology company being spun out of UMDNJ .The company will pursue utilizing a cancer molecular signature (Fry) that they have primarily characterized in a breast cancer model. Their findings suggest that Fry could be used as a platform to develop cancer-gene based susceptibility tests, genetic and immunological companion diagnostics, as well the discovery of new drugs for aggressive and/or advanced breast cancer in particular.
Grace Therapeutics LLC
Grace Therapeutics LLC is a start-up life science company. Their goal is to develop improved formulations of select approved drugs including combination drugs for existing and/or additional therapeutic indications. They also intend to develop innovative drug delivery systems that improve the clinical outcome of currently marketed products. Their management team and network of consultant experts are experienced at founding and growing companies from the earliest stages of development through product approval and commercialization.
Hudson BioPharma, Inc.
Hudson BioPharma Inc. has incorporated in New Jersey and was created to develop anti-cancer medicines through utilization of their proprietary technology in the design and synthesis of drug leads targeting protein-to-protein interaction. The primary focus of Hudson BioPharma will be on utilizing tumor protein P53 (a natural tumor suppressor that regulates cell division by keeping cells from growing and dividing too fast or in an uncontrolled way), to develop an anti-cancer medicine.
Hurel Corporation provides patented micro fluidic devices and cell culture that elevate the metabolic competency and endurance of cells cultured in vitro, and that simulate pharmacokinetic interactions among multiple tissues and organs. These proprietary capabilities produce unrivaled levels of physiologically relevant predictive sensitivity- “human relevance”- that define the current state of the art of hepatic and multi-tissue cell-based assays.
Kamat Pharmatech, LLC
Kamat Pharmatech, LLC is a newly formed company that will operate as a contract research organization while developing its own technology focussing in the area of injectable products such as anti-inflammatory drugs that target autoimmune diseases.
Nexomics Biosciences, Inc.
Nexomics Biosciences, Inc. is a Rutgers spinout focusing on the discovery, development and commercialization of novel drugs for cancer, antiviral and antibiotic treatments. Additionally, Nexomics Biosciences functions as a contract research organization (CRO), offering a broad array of gene-to-structure services to the biopharmaceutical community.
Novanex is a US-based medical device company that develops and commercializes innovative device and technology to monitor or detect disease conditions or status. Their first developmental product, OMC100, monitors and displays the blood glucose level non-invasively in two minutes. The system is designed for use in hospitals as well as in outpatient sites and homes.
NutraSorb, LLC pioneers the use of a proprietary, groundbreaking process that naturally concentrates the beneficial phytonutrients from fruits and vegetables into foods in amounts sufficient to promote health and wellness. The science-based, tasty, natural and shelf-stable functional foods and ingredients deliver an effective daily dose of antioxidants, polyphenols and other phytonutrients in a few servings, while reducing sugars and unwanted calories. NutrasorbTM technology is green and environmentally friendly, generating no waste or pollution. It was invented by leading researchers from major US universities, who joined forces to create a new generation of innovative, nutritional products for the benefit of humankind.
OncoDe-Med Inc. is a New Jersey based High-Tech Corporation focused on cutting- edge technologies involved in the early diagnosis and follow-up of human tumors.
OncoDe-Med, Inc. has developed a Multifunction Aspiration (MFADx™) system, which is a novel, user-friendly, disposable, proprietary tumor cell/tissue collecting and processing device with a removable safety needle. The MFADxTM is designed for the specific demands of aspiration: For easier sample processing and increased need for greater tissue or cell sample sizes.
PDS Biotechnology Corporation
PDS Biotechnology is harnessing the newly discovered properties of specific synthetic positively charged (cationic) lipids to develop a new generation of more versatile, simpler, safer and significantly more potent B- and T-cell activating vaccines. PDS’s proprietary Versamune™ platform nanotechnology when combined with T-cell antigens leads to superior cures for infection and cancer.
QualComp Consulting Services
QualComp Consulting Services specializes in the application of effective quality systems for Pharmaceutical, Biotechnology and Medical Device companies. Using proven project management, risk management and design controls expertise, QualComp is a trusted partner in ensuring the safety and efficacy of your products.
QualComp Consulting Services was founded in 2008 and has since grown to include consultants located throughout the United States and Canada. Our team is comprised of experts who bring to our clients the application of compliant best industry practices.
Shionogi Inc. is the U.S. based group company of Shionogi & Co., Ltd., a leading Japanese pharmaceutical company. Shionogi Inc., develops and commercializes pharmaceutical products that address unmet medical needs. Together with their Japanese corporate parent, Shionogi has been providing innovative medicines essential to people’s health. Shionogi’s products in development seek to help patients with a variety of diseases and conditions, including male sexual health, pediatric conditions, women’s health, HIV, pain and diabetes. Shionogi has set up a non-GMP testing laboratory at CCIT to bring its product research work in-house.
SkinAxis, LLC is a biotechnology company providing unique research and development services for the pharmaceutical, biotechnology, chemical, and cosmetic industries involved with drug and active ingredient discovery. Their exclusive in-house technology provides important, reliable, and previously unobtainable data on human skin and lip responses for drug and active ingredient discovery.
TAXIS Pharmaceutical is focused on pharmaceutical discovery and development of antimicrobials targeting drug-resistant bacterial pathogens. They are currently in the process of commercializing a novel class of small-molecule compounds based on exclusive worldwide rights to the IP jointly owned by Rutgers and UMDNJ.
Urigen Pharmaceuticals Inc.
Urigen Pharmaceuticals specializes in the design and implementation of innovative products for patients with urological ailments including, specifically, the development of innovative products for amelioration of Painful Bladder Syndrome (PBS), Urethritis, Nocturia and Over Active Bladder (OAB).
V ClinBio is a scientific research organization (SRO) that provides services in translational, clinical and preclinical research for advancing drug discovery, personalized therapeutics, biomarkers research and clinical diagnostics validation. V ClinBio provides research services for small and large molecules discovery in multiple biology and disease areas. V ClinBio’s translational research is engaged in functional assays and biomarkers research, early-stage, mechanism of action (MoA) and proof-of-concept (PoC) studies using clinical samples. V ClinBio is also engaged in investigating novel and established diagnostics for disease prognosis and susceptibility, and pharmacogenomics for advancing personalized / stratified therapeutics. It collaborates with diagnostic partners to test and validate kits/panels in oncology, psychiatry and other disease areas. V ClinBio is adept in executing animal toxicology and pharmacology studies in multiple disease models. V ClinBio also works with clinical trials group in the areas of investigative biomarkers and patient stratification strategies.
Vasade Biosciences, Inc.
Vasade Bioscience Inc. is a growth-stage biotechnology company committed to the pre-clinical discovery and development of cardio protective and vascular protective molecules, drugs, and devices for the prevention, treatment, and management of cardiovascular disease, the leading cause of death worldwide. By combining its unique expertise in animal models of cardiovascular diseases with state-of-the-arts genetic, genomic, and proteomic technologies. Vasade has positioned itself in the development of novel cardiovascular therapeutic drugs for the treatment of cardiac hypertrophy, coronary artery disease, myocardial infarction, and heart failure. Their development pipeline focuses on the rational discovery, design, and development of small molecules, peptides, and gene therapies targeting novel cell-signaling molecules that influence cardiac cell growth and survival.
VESAG Health Inc.
VESAG is a Mobile Personal Emergency Response System (MPERS) designed to track patient vitals, providing pre-emptive medical care and avoiding emergencies. The medical watch includes tracking features and collects patient parameters such as pulse, ECG/EKG, pulse, oxygen saturation, body weight, heart rate and blood pressure. All data is wirelessly transmitted to a web portal for monitoring by a medical call center. The device can be worn as a watch or a pendant and does not confine the wearer’s location due to the use of GPS and GSM technologies.